200 results about "Insulin sensitivity" patented technology

The invention relates to an integrated management system for diabetic patients, which comprises the following steps of: constructing a high-dimensional metabolic data model, performing multi-modal fusion on genome information, metabolome data and life behavior data, and mining a potential mode of metabolic characteristics of the patients; carrying out patient typing by utilizing a clustering algorithm comprising a self-organizing mapping network, and identifying different metabolism types comprising an insulin resistance type and an insulin secretion insufficiency type; developing a hierarchical management strategy based on a typing result, wherein the hierarchical management strategy comprises diet, exercise and medicine intervention schemes for different types; collecting dynamic quantitative indexes of the metabolic load, and integrating the blood glucose fluctuation amplitude, insulin sensitivity and daily nutrition intake of the patient; constructing a metabolic load prediction model, and combining a time sequence deep learning algorithm with real-time data, including blood glucose, diet and exercise, of a patient to measure a future metabolic load; and establishing a causal relationship model between patient behaviors and metabolic reactions, and analyzing an interaction mode of diet, exercise and metabolic loads by adopting a causal inference technology.

The invention discloses a personalized medical health service recommendation system based on big data analysis, and belongs to the technical field of medical health services. The synchronization module is used for generating a standardized data stream according to dynamic blood glucose monitoring data and an original heart rate variability signal; the analysis module is used for generating a diet time sequence data stream according to the intake event timestamp; the blood glucose feature extraction module is used for extracting data from the standardized data stream; the insulin sensitivity analysis module is used for generating an insulin sensitivity factor matrix; the nutrition analysis module is used for generating a carbohydrate equivalent time distribution vector and a dietary fiber intake intensity value; the feature fusion module is used for generating a fusion feature vector according to the blood glucose drift trend coefficient, the insulin sensitive factor matrix and the carbohydrate equivalent time distribution vector; the risk assessment module is used for generating a hypoglycemia risk probability value according to the fusion feature vector; and the recommendation generation module is used for generating a personalized service recommendation set according to the hypoglycemia risk probability value.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

The invention relates to a lactic acid bacterium capable of reducing fat, resisting inflammation and reducing blood sugar, which is classified and named as pediococcus acidilactici XJ335, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30093, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can achieve the fat reducing effect by adjusting the abundance of intestinal flora; the levels of IL-6 and TNF-alpha in serum of diabetic mice are remarkably improved through regulation, so that the anti-inflammatory effect is achieved; various cardiovascular diseases of atherosclerosis are prevented by adjusting the levels of TC, TG, HDL-C and LDL-C; by reducing FINS and HOMA-IR levels and improving HOMA-IS, HOMA-beta and QUICKI value levels, insulin resistance of a body is reduced, insulin sensitivity and pancreas islet beta cell functions of the body are improved, gene expression related to blood sugar regulation is regulated, and an excellent blood sugar reducing effect is achieved in the body.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention relates to the technical field of insulin resistance reversal, in particular to a composition with an insulin resistance reversal component and a preparation method thereof.The composition comprises quercetin, procyanidine, malic acid, magnesium carbonate, zinc lactate and cereals, fasting blood glucose, fasting insulin and an insulin resistance index can be reduced through synergistic interaction of all the components, and the insulin resistance index can be reduced; according to the traditional Chinese medicine composition, the insulin sensitivity index is improved, and the problems that in the prior art, traditional Chinese medicine compositions are complex in component, effective components capable of reversing insulin resistance and the synergistic mechanism are unclear, and the content of the effective components in the same medicine is inconsistent due to the influence of the growth environment, so that the treatment effect is unpredictable are solved.

The invention provides a preparation method of probiotic fermented polygonatum sibiricum polysaccharide, and belongs to the field of traditional Chinese medicinal material processing. The preparation method comprises the following steps: (1) adding cellulase and pectinase into polygonatum kingianum, carrying out water extraction, carrying out enzyme deactivation after water extraction, and carrying out suction filtration to obtain filtrate; (2) preparing bacillus DU-106 and lactobacillus plantarum nbk-MA2 into bacterial powder, and adding water to obtain bacterial liquid; mixing the bacterial liquid with the filtrate, fermenting, performing suction filtration, and centrifuging to obtain supernate; performing alcohol precipitation to remove protein; carrying out ethanol precipitation by using absolute ethyl alcohol again, collecting the precipitate after centrifuging, and carrying out redissolution, dialysis and freeze-drying to obtain fermentation modified crude polysaccharide; and (3) purifying the fermented and modified crude polysaccharide to obtain a purified polysaccharide component. The obtained probiotic fermented polygonatum sibiricum polysaccharide has the effect of losing weight, and can obviously improve the obesity characteristics of mice, specifically, reducing body weight, reducing fat, reducing serum liver lipid level, relieving serum liver inflammation of the mice, weakening blood glucose insulin sensitivity, repairing liver injury and the like.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention relates to the technical field of biology, in particular to a method for relieving high-starch-induced liver injury and glucose metabolism disorder of perches. The feed formula provided by the invention comprises the following components in percentage by weight: 20-22% of cassava starch, 2-6% of mulberry leaf polysaccharide and the like. The mulberry leaf polysaccharide and high-content starch in the feed form efficient synergy, so that the growth performance of the weever is remarkably improved, accumulation of liver glycogen and fat is effectively reduced, and the health condition of the liver is remarkably improved; meanwhile, the blood sugar regulation capability of the weever is also optimized, the insulin resistance caused by high starch diet is reduced, and the insulin sensitivity is enhanced; and by activating a PI3K / Akt signal path and other mechanisms, a glucose metabolism path is optimized, and efficient utilization of energy is promoted. The feed disclosed by the invention is economical and efficient in formula, provides solid scientific support for healthy culture of perches, and powerfully promotes sustainable development of aquaculture industry.

The invention discloses a microneedle raw material composition, a microneedle formed by the microneedle raw material composition and an ultrasonic regulation and control gene editing system, the microneedle raw material composition comprises CRISPRa-UCP1 plasmid (aUCP1) loaded in a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) and used for up-regulating UCP1, and the MOF is MOF modified by mPEG-PEI. And the browning of white fat cells is promoted through the controllable release of the CRISPRa-UCP1 system. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound. The research provides a new standard treatment mode for gene therapy of obesity and other metabolic diseases.

The invention relates to a mitochondrial uncoupling inhibitor sustained-release nanodot, a preparation method thereof and application of the nanodot in type 2 diabetes mellitus, and belongs to the technical field of nano-drugs. According to the preparation method disclosed by the invention, glycine and genipin are subjected to Schiff reaction to prepare the slow-release nanodot, and the slow-release nanodot is of a monodisperse spherical structure, has surface negative charges, and can slowly release genipin under physiological conditions, so that the mitochondrial protection effect of the genipin is fully exerted. The mitochondrial uncoupling inhibitor slow-release nanodot prepared by the invention can obviously improve the mitochondrial membrane potential, increase the cell ATP content, effectively inhibit mtDNA release under the stimulation of IL-1beta and palmitic acid, effectively inhibit STING inflammation pathway activation under the stimulation of IL-1beta and PA, obviously reduce pancreatic beta cell apoptosis, obviously relieve endoplasmic reticulum stress, and can be used for preparing the mitochondrial uncoupling inhibitor slow-release nanodot. The T2DM mouse blood sugar is obviously reduced, the glucose tolerance dose and the insulin sensitivity are improved, and good biocompatibility is achieved.

The invention discloses mesoporous polydopamine nanoparticles loaded with texipatide as well as a preparation method and application of the mesoporous polydopamine nanoparticles. The preparation method of the mesoporous polydopamine nanoparticles loaded with the texipatide comprises the following steps: firstly, mixing dopamine hydrochloride and a nonionic copolymer under the condition of a solvent, then sequentially adding a hydrophobic pore-enlarging agent and a catalyst, and reacting to obtain the mesoporous polydopamine nanoparticles, the preparation method comprises the following steps: preparing mesoporous polydopamine nanoparticles, dispersing the mesoporous polydopamine nanoparticles in a water solvent, adding texipatide, and carrying out a mixing reaction to obtain the texipatide-loaded mesoporous polydopamine nanoparticles. The mesoporous polydopamine nanoparticles loaded with texipatide prepared by the preparation method not only have excellent drug encapsulation efficiency and drug slow release effect, but also can effectively reduce the body weight and random blood glucose of a patient and remarkably improve the glucose tolerance and insulin sensitivity of the patient when being used for treating obesity, so that the mesoporous polydopamine nanoparticles loaded with texipatide can be used for treating obesity. And an energy consumption rate.

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

The invention discloses a microneedle raw material composition as well as a microneedle and a sonodynamic system formed by the microneedle raw material composition. The microneedle raw material composition comprises a zinc-based porphyrin metal organic framework MOF (Zn-TCPP) modified by mPEG-PEI. The sonodynamic system provided by the invention can kill redundant white fat cells. Obese mice treated with this ultrasound gene therapy show significant improvements in glucose tolerance and insulin sensitivity, successfully achieving weight loss and inhibiting weight rebound.

The invention discloses a pharmaceutical application of a 3-phenylglutaric acid derivative and a pharmaceutical composition. The 3-phenylglutaric acid derivative can be used for preparing an FASN inhibition drug. The 3-phenylglutaric acid derivative micromolecule 84-B10 can inhibit FASN in a targeted manner, is used for inhibiting the activity of the FASN, promoting the degradation of the FASN and relieving weight gain, liver fat accumulation, insulin sensitivity decline and glucose tolerance impairment caused by high calorie intake, and can be used for preparing medicines for preventing and treating metabolism-related fatty liver diseases.

The application discloses a benzothiophenone derivative, a preparation method and application thereof. The benzothiophenone derivative, a tautomer, an optical isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and the chemical structure of the benzothiophenone derivative is shown as formula (I), wherein R is any one of the following groups: a substituted alkane and N-benzyl-2-chloroformamide. The benzothiophenone derivative can regulate a PPARγ target as an anti-type 2 diabetes drug, can reserve insulin sensitivity, can avoid related side effects caused by a PPARγ full agonist, and has a 'highly efficient and safe' hypoglycemic effect.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present application relates to the technical field of reversing insulin resistance, and particularly relates to a composition with components for reversing insulin resistance and a preparation method thereof, the composition comprising quercetin, procyanidin, malic acid, magnesium carbonate, zinc lactate and grains, and through synergistic effects of the components, the composition can reduce fasting blood glucose, fasting insulin and insulin resistance index, and improve insulin sensitivity index, and overcomes the problems in the prior art that the components of the traditional Chinese medicine composition are complex, the effective components for reversing insulin resistance and the synergistic mechanism are not clear, and the content of the effective components in the same medicine is not consistent due to the influence of the growth environment, resulting in unpredictable treatment effect.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

The invention provides a method for detecting insulin sensitivity, which comprises the following steps: (1) transfecting a cell to be detected by using a GLUT4myc cDNA plasmid: transfecting the cell to be detected by using the GLUT4myc cDNA plasmid, so that the cell stably expresses GLUT4myc; (2) measuring the endocytosis rate of the GLUT4myc: performing endocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody to be endocytosed, and regularly detecting the amount of the GLUT4myc combined with the anti-myc antibody remained on the surface of the cell; (3) measuring the GLUT4myc exocytosis rate: performing exocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody in the cell to exocytosis, and regularly detecting the translocation amount of the GLUT4myc combined with the anti-myc antibody in the cell to the surface of the cell; (4) calculating the difference value between the GLUT4myc exocytosis rate and the GLUT4myc endocytosis rate, and calculating the insulin sensitivity according to the difference value; the insulin sensitivity evaluation method has the beneficial effects that the insulin sensitivity is evaluated by detecting the exocytosis and endocytosis rates of fat cells, muscle cells or peripheral blood lymphocytes GLUT4, so that early-stage diabetic patients can be identified, and the pathogenesis of diabetes mellitus can be researched.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

A method of determining an insulin bolus to be administered by an insulin delivering device is disclosed. According to the inventive method, glucose measurement data corresponding to glucose level measurement signals detected by a continuous glucose sensor are received. An insulin bolus to be administered by the insulin delivering device is determined based on a formula having expressions indicative of, for example, glucose level derived from the glucose measurement data, carbohydrate-to-insulin ratio (CIR) and an insulin sensitivity factor (ISF). The method can be carried out using a processor of a device such as insulin pen, an insulin pump, a remote control device configured to remotely control an insulin pump or an insulin pen, a continuous glucose meter, a controller of a continuous glucose meter, a blood glucose meter, and a portable electronic device such as a smart phone, smart watch or tablet.

The method comprises the following steps: amplifying SIRT3 and SIRT4 genes from human, cloning the SIRT3 and SIRT4 genes to a plasmid vector to construct a pSIRT3-4 plasmid, and mediating the simultaneous expression of the two genes by using an internal ribosome entry site (IRES). According to the present invention, the insulin resistance (IR) model of the HepG2 cell is established by using the 35mM high glucose solution, and after the transfection of the pSIRT3-4 plasmid, the uptake of glucose is improved, the conduction of the insulin signal is recovered, the sensitivity of the HepG2 cell to the insulin is improved, the IR is improved, and the dysfunction of the mitochondria is recovered. The pSIRT3-4 plasmid is wrapped by insulin-coupled cationic liposome and is applied to an IR mouse model, and research proves that lipid accumulation in the IR mouse liver is obviously reduced, and the mitochondrial function of the IR mouse liver is obviously improved. The pSIRT3-4 plasmid constructed by the invention provides a new gene therapy means for the treatment of insulin resistance.

The present invention relates to a peptide conjugate having anti-diabetic activity and uses thereof. The peptide conjugate of the present invention exhibits blood glucose level lowering efficacy by promoting glucose absorption into cells, suppressing insulin resistance signals, promoting insulin sensitivity signals, and suppressing the death of pancreatic β cells, which are insulin-producing cells. The present invention also relates to a peptide having anti-diabetic and anti-obesity activities and uses thereof. The peptide of the present invention has activities of suppressing insulin resistance signals, promoting insulin sensitivity signals, and promoting fat breakdown in adipocytes.

The invention aims to provide a peptide for accelerating fat metabolism and application thereof, the peptide is prepared into a product convenient to use, and the amino acid sequence of the peptide is MVHSYSETSD. The peptide is obtained through peptide library screening, bioinformatics analysis screening and fat cell decomposition experiment verification, and it is verified that the active peptide obtained through screening has the effects of accelerating fat metabolism, inhibiting fat accumulation, reducing blood fat and body fat content and reducing body weight; the insulin sensitivity and the glucose tolerance are improved, and the prevention and treatment effects on obesity and complications thereof are realized.

The invention relates to the technical field of novel application of targeted drugs, in particular to application of Plitidepsin in preparation of drugs for treating obesity and improving glucose metabolism. It can be known through exploration that plitidepsin can reduce the weight and fat content of a treated object and the content of white adipose tissue around inguinal white fat and epididymis, and meanwhile, the sugar tolerance and insulin sensitivity of the treated object can be improved. Therefore, the plitidepsin can be used for preparing the medicine for treating obesity and improving glucose metabolism.

To provide modified or polymer conjugated MetAP2 inhibitors.SOLUTION: The present invention relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.SELECTED DRAWING: Figure 1